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Despite the wide application of prostate-specific antigen-based screening leading to a 
profound stage migration in prostate cancer (PC), a significant percentage of men are 
still being diagnosed with clinically high-risk disease that requires aggressive 
treatment. Optimal management in these patients remains challenging, and strong 
advocates for radical prostatectomy (RP), radiotherapy, androgen deprivation therapy, 
and, increasingly, a multimodal approach abound. Currently, surgery for high-risk PC 
is frequently applied. RP offers an attractive opportunity for tumor excision either as 
a definitive management or as a first step in multimodal therapy. Nevertheless, this 
approach is still controversial. In this review, we discuss the current evidence for the 
role of RP in this clinical setting, including surgical considerations and outcomes. The 
role of robot-assisted RP, which is increasingly utilized in Korea in this clinical scenario, 
is discussed.
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INTRODUCTION
Approximately 15% to 26% of patients with prostate cancer 
(PC) will present with high-risk disease despite pros-
tate-specific antigen (PSA) screening [1,2]. High-risk dis-
ease is understood to be a significant predictor of pro-
gressive, symptomatic disease or death from PC [3]. The 
widely accepted definition of high-risk PC was first pro-
posed by D’Amico on the basis of a pretreatment Gleason 
score of 8, a clinical stage of at least T2c, or a presenting 
PSA level of 20 ng/mL [4]. 
The optimal management of patients with high-risk PC 
remains controversial [5-7]. Available therapeutic options 
include monotherapy by radical prostatectomy (RP) or 
combined modality approaches that include local treat-
ments such as radiotherapy (RT) along with androgen dep-
rivation therapy (ADT) or chemotherapy. High-risk PC pa-
tients are at increased risk of locally advanced or micro-
metastatic disease; therefore, it is reasonable to employ a 
more aggressive treatment plan targeting the local as well 
as the systemic components of the disease [8,9]. Considerations 
for surgical management were often discarded in such in-
dividuals owing to the increased risk of biochemical re-
currence (BCR), systemic progression, and worse oncologic 
outcomes [10,11]. 
Currently, several studies have shown comparable onco-
logic outcomes for RP relative to RT or ADT in the context 
of high-risk disease [12-15]. Zelefsky et al. [16] showed that 
RP was associated with a nearly 10% lower risk of pro-
gression to metastasis and a lower cancer-specific mortal-
ity (CSM) compared with high-dose RT in patients with 
high-risk PC. The 10-year outcomes from the Cancer of the 
Prostate Strategic Urological Research Endeavor 
(CaPSURE) database for men with high-risk PC treated 
with RP showed 90% local recurrence-free survival, 89% 
systemic progression-free survival (PFS), 95% cancer-spe-
cific survival (CSS), and 80% overall survival (OS) [17]. 
Even in the very-high-risk category using the Cancer of the 
Prostate Risk Assessment (CAPRA) score, approximately 
20% of men will be cured with RP alone [2,18]. 
High-risk PC patients treated with RP have variable sur-
vival outcomes, according to different high-risk definitions. 
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TABLE 1. Definition of high-risk prostate cancer
Definition Source or Utilized by
PSA≥20 ng/mL or GS 8–10 or clinical stage≥T2c
PSA≥20 ng/mL or GS 8–10 or clinical stage≥T3a
PSA≥20 ng/mL or GS 8–10 or clinical stage≥T3a or Any two of 
the following: T2b/c, GS 7, PSA 10–20 ng/mL
PSA 20–100 ng/mL, biopsy GS 8–10, and any clinical T stage 
or PSA<100 ng/mL, GS 8–10, and clinical stage≥T2c
Combination of age, PSA value, clinical stage, biopsy GS, and 
percentage of positive biopsy cores
D’Amico et al. [4]
American Urological Association [20]
European Association of Urology [21]
UK National Institute for Health and Clinical Excellence [62]
National Comprehensive Cancer Network [22]
The Radiation Therapy Oncology Group [23]
The Cancer of the Prostate Risk Assessment score [31]
PSA, prostate-specific antigen; GS, Gleason score.
Nevertheless, independent of the definition, highly con-
vincing, long-term CSS rates have been described. Frequent 
downgrading and downstaging, and a possible therapeutic 
role of local tumor debulking, support RP and extended pel-
vic lymph node dissection (e-PLND) as primary manage-
ment strategies during multimodality treatment [19]. 
However, many guidelines are reluctant to endorse RP as 
an equivalent treatment to RT and ADT [18]. 
The aim of this review was to define high-risk PC and to 
elaborate on the emerging evidence to support the role of 
RP as both a monotherapy and as part of a collaborative, 
multimodal approach in high-risk localized PC. The role of 
robot-assisted RP (RARP), which is increasingly being uti-
lized in Korea for the surgical treatment of PC in this clin-
ical scenario, is discussed.
WHAT IS HIGH-RISK PROSTATE CANCER?
Table 1 summarizes the contemporary and most widely 
used definitions of high-risk PC. The exact definition of 
high-risk PC is unclear, and a consensus has not yet been 
reached. This lack of consensus on a definition of high-risk 
disease represents a critical barrier for patient counseling, 
comparative assessment of treatment outcomes, and the 
design of randomized trials. High-risk, clinically localized 
disease was classically defined by D’Amico et al. [4] as any 
combination of the following factors: a PSA greater than 20 
ng/mL, a Gleason score of 8 to 10, or a clinical stage of T2C 
or higher. The American Urological Association (AUA) has 
endorsed these D’Amico high-risk criteria [20]. More re-
cently, the National Comprehensive Cancer Network 
(NCCN) and the European Association of Urology (EAU) 
modified this definition to include any combination of a 
clinical T3 stage, a PSA score greater than 20 ng/mL, or a 
Gleason score of 8 to 10 [21,22]. The Radiation Therapy 
Oncology Group also described a classification system to 
predict overall and cause-specific survival [23]. However, 
an estimation of patients’ risk of progression with this defi-
nition is far from perfect, because these criteria encompass 
a heterogeneous group of patients. 
Clinical stage is often inaccurate in localized PC. Digital 
rectal exams fail to detect extracapsular extension in 30% 
to 50% of patients. The role of clinical stage remains con-
troversial, because it does not necessarily add information 
and displays interobserver variability [5,24,25]. In a recent 
review of the CaPSURE database, an inaccurate clinical 
stage was assigned to 35.4% of patients [24,26]. Pretreatment 
PSA can reflect not only cancer, but benign prostatic hyper-
plasia or chronic inflammation [27]. Finally, biopsy down-
grading after the final pathological assessment is a com-
mon phenomenon, occurring in up to 45% of cases [28,29]. 
Because of these limitations, several multivariate risk 
assessment tools have been developed. The Kattan pre-
operative nomogram uses a multivariate model that com-
bines stage, PSA, and additional prostate biopsy in-
formation to generate an estimate of the risk of treatment 
failure following RP [30]. Recently, Cooperberg et al. [31] 
developed another high-risk PC definition: the CAPRA 
score. They added secondary parameters, including pros-
tate biopsy profiles (biopsy Gleason score and percentage 
of positive biopsy cores) and patient age to the existing basic 
parameters. The CAPRA score ranges from 0 to 10, and a 
CAPRA score of 6 to 10 represents high-risk PC. This tool 
was recently updated, because both the CAPRA post-
surgical score (CAPSA-S) and postoperative pathologic re-
sults can be used to predict BCR after RP on a continuous 
scale. Additional variables such as extent of cancer in nee-
dle biopsy, pretreatment PSA velocity, PSA doubling time, 
or the presence of a tertiary Gleason pattern have been sug-
gested to optimize risk stratification [32]. 
To be clinically useful, criteria defining high-risk PC 
should reliably distinguish patients whose cancer is ame-
nable to cure with local therapy alone from those who may 
require additional systemic therapy. Novel molecular 
markers that can both significantly enhance the prediction 
of relapse following therapy and identify locally advanced 
and occult metastatic disease are needed. Incorporating 
several known risk factors together with endorectal mag-
netic resonance imaging findings, pretreatment PSA ve-
locity, and additional data from prostate biopsies may pro-
duce a more precise, high-risk disease definition.
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TABLE 2. Outcomes of radical prostatectomy as monotherapy in high-risk prostate cancer
Source Cases Definition OCD (%)
Median 
follow-up
BCR-free 
survival
CSS MFS OS
Gerber et al. [63] 242 cT3 9 - 29% at 5 y 57% at 10 y 32% at 10 y -
Yossepowitch et al. [64] 957 D’Amico 43 4.3 y 68% at 5 y, 
59% at 10 y
- - -
Stephenson et al. [65] 1,962 D’Amico - 48 mo - 92% at 10 y, 
81% at 15 y
- -
Loeb et al. [39] 175 D’Amico 36 8 y 68% at 10 y 92% at 10 y 84% at 10 y -
Walz et al. [11] 887 D’Amico - 2.4 y 47.4% at 5 y, 
35.7% at 10 y
- - -
van den Ouden et al. [66] 83 cT3 18 52 mo 29% at 5 y 85% at 5 y, 
72% at 10 y
69% at 5 y, 
50% at 10 y
75% at 5 y, 
60% at 10 y
OCD, organ-confined disease; BCR, biochemical recurrence; CSS, cancer-specific survival; MFS, metastasis-free survival; OS, overall 
survival. 
RATIONALE FOR SURGERY FOR HIGH-RISK 
PROSTATE CANCER 
Traditionally, RP was not considered a viable treatment 
option for high-risk PC cases [33]. However, several recent 
studies of high-risk PC have presented another view (Table 
2). In some high-risk PC patients, RP is a one-step modality 
for a cure, with excellent oncological prognosis. One of the 
most important benefits of RP compared with nonsurgical 
therapy is pathologic staging of both the primary cancer 
and regional lymph nodes. Although preoperative risk 
group stratification and nomograms may identify patients 
with adverse features, studies have established that 
pathologic variables, such as pathologic Gleason pattern 
and stage, more accurately predict who may benefit from 
additional therapy. In favorable situations, pathologic 
downgrading and downstaging at RP may potentially 
spare patients from receiving adjuvant therapy. In a re-
view of the CaPSURE database, an inaccurate clinical 
stage was assigned to 35.4% of patients [24]. About 
one-third of high-grade (8-10) biopsy Gleason scores were 
subsequently downgraded at RP and 26% to 31% were 
shown to have organ- or specimen-confined disease [34,35]. 
A study by Abern et al. [36] on this issue of PC adds sig-
nificantly to the literature by demonstrating that patho-
logic downstaging occurs more frequently than previously 
reported and that patients who were downstaged had sur-
vival outcomes that were similar to those of patients with 
intermediate- and low-risk PC. 
Lymphadenectomy at the time of RP confers information 
about the level and extent of nodal involvement and may 
guide the initiation of earlier adjuvant ADT [37]. Multiple 
series suggest an approximately 10% to 20% 10-year dis-
ease-free recurrence without adjuvant therapy following 
lymph node dissection for men with lymph node meta-
stases [38]. Another potential benefit of RP for high-risk 
disease is the possible posttreatment avoidance of addi-
tional therapy. 
Approximately one-half of men with high-risk disease 
will be cured with RP monotherapy and thus avoid any fur-
ther treatment [9,39,40]. In one study, Yossepowitch et al. 
[41] found that 35% to 76% of high-risk patients avoided 
secondary therapy altogether 10 years after surgery. 
Joniau et al. [42] reported on a cohort of 51 men with very 
high-risk PC (cT3b-T4), in which 31.4% avoided ADT, and 
after a median follow-up of 9 years, the 10-year biochemical 
PFS (BPFS) rate was 45.8%. Using CaPSURE data, Meng 
et al. [17] showed that men receiving RT for high-risk PC 
are 3.5 times as likely to receive ADT as are patients treated 
with RP. Even if men ultimately require salvage ADT for 
disease control after RP, they may delay the time to ini-
tiation of ADT. In a study by the Mayo Clinic on patients 
with cT3 disease, the average duration of freedom from 
ADT after RP monotherapy was 4.0 years [43]. 
Another advantage of RP is the expectation and sig-
nificance of nondetectable PSA. After RP in completely ex-
cised patients, serum PSA should decline to a non-
detectable level. The sensitivity of post-RP PSA provides 
a prompt assessment of disease cure and control, allowing 
early recognition of recurrent disease and delivery of sal-
vage RT if necessary. Primary treatment with RP allows 
for salvage RT with curative intent in the setting of a 
promptly recognized local recurrence. Even in patients 
with poorly differentiated disease and positive margins, re-
currence after RP can be effectively treated with salvage 
radiation that may prevent metastatic progression. 
Adjuvant or salvage RT cures another 50% of recurrences, 
representing a three-fold reduction of death from PC after 
surgery with minimal additional morbidity [44].
ROLE OF SURGERY IN THE TREATMENT OF 
LOCALLY ADVANCED PROSTATE CANCER 
Until recently, surgical treatment had not been used in lo-
cally advanced PC. The role of RP in patients with locally 
advanced PC has been debated, because the combination 
of RT and hormone therapy is coming to be used more fre-
quently for locally advanced PC. Today, according to the 
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EAU and AUA guidelines, RP is a reasonable treatment op-
tion for selected PC patients with cT3a disease, a Gleason 
score of 8 to 10, or PSA>20 [21]. Moreover, surgery is consid-
ered by the NCCN to be an acceptable primary treatment 
option for selected patients with low-volume, high-risk PC 
and a limited number of adverse prognostic factors [45]. In 
a series from the Memorial Sloan-Kettering Center, of 176 
men with cT3 over a 20-year period, the role and effective-
ness of RP were reviewed. Within this cohort, only 64 men 
received neoadjuvant hormone therapy. Fifty-three pa-
tients were downstaged to organ-confined disease after 
pathological evaluation, and more than one-half (52%) of 
patients remained free of disease recurrence following RP 
[46]. In a Mayo Clinic study of men undergoing RP, cT3 was 
found in 841 of the 5,662 patients (15%) studied. Of these 
841, 661 men (79%) did not receive neoadjuvant hormone 
therapy. After a pathological review of these patients, 223 
(27%) were found to be overstaged, and in fact had or-
gan-confined disease [35]. It is important to note that sur-
gery can identify a substantial subset of men with favorable 
features in whom additional therapy is not indicated. 
Another feature to attribute a very high-risk stratification 
is the presence of positive regional lymph nodes [19]. 
Recently, Engel et al. [47] found a doubled risk of overall 
mortality when RP was abandoned compared with com-
pleted RP for patients in whom positive lymph nodes were 
found at the time of surgery. They concluded that RP may 
have a survival benefit, and the abandonment of RP in 
node-positive cases may not be justified. A systematic re-
view by Verhagen et al. [48] concluded that there was a clin-
ically important survival benefit in men with node-positive 
disease who received ADT when local control of the primary 
tumor is achieved. 
ROBOTIC PROSTATECTOMY FOR HIGH-RISK 
PROSTATE CANCER 
Traditionally, RP in high-risk PC is performed by use of an 
open approach. During the last several years, however, an 
increasing number of publications have discussed the use 
of minimally invasive techniques, particularly RARP [42]. 
The increasing availability of robotic technology to urolo-
gists has expanded the roles and indications for RARP, in-
cluding recent reports of this approach in a high-risk 
setting. A recent retrospective analysis studied 913 pa-
tients with high-risk PC treated with open RP or minimally 
invasive RP with e-PLND and aimed to compare the patho-
logical and short-term BCR-free survival outcomes for dif-
ferent therapeutic approaches. Of all patients, 81.4% un-
derwent open RP, 11.5% underwent RARP, and 7.1% un-
derwent laparoscopic RP (LRP). The authors demon-
strated BCR-free survival rates of 56.3%, 67.8%, and 
41.1%, respectively, and positive surgical margin (PSM) 
rates of 29.4%, 34.3%, and 27.7% for open retropubic RP, 
RARP, and LRP, respectively. An e-PLND was performed, 
and 10.8% of positive nodes were found in the open retro-
pubic RP group compared with 3.5% in the minimally in-
vasive RP group. The authors concluded that equivalent 
rates of PSM and short-term BPFS between open RP and 
minimally invasive RP were observed [49]. However, major 
limitations were differences in the cumulative number of 
high-risk factors, short follow-up, nonstandardized 
e-PLND, and nerve-sparing indications. 
Punnen et al. [50] compared outcomes of 233 high-risk 
RARP cases with 177 high-risk RRP cases from a single 
institution. RARP patients had less blood loss and similar 
pathological outcomes compared to RRP patients. Overall 
PSM rates were 29% and 23%, respectively, and RFS rates 
at 4 years were 66% and 79% for RARP and RRP, 
respectively. Similarly, Busch et al. [51] noted that RARP 
demonstrated similar oncologic outcomes compared to 
RRP and LRP in a propensity-score-matched cohort of pa-
tients with high-risk PC. 
Strong debate surrounds the feasibility and role of ro-
botic surgery in performing e-PLND. A recent series of 143 
robotic e-PLND patients with intermediate or high-risk PC 
according to the D’Amico classification showed a median 
number of 20 (range, 9–65) excised nodes with positive node 
rates of 13% and without Clavien-Dindo complications in 
82% of cases, thus confirming the technical feasibility of the 
procedure with minimally invasive surgery [52]. These 
promising results must be confirmed by randomized clin-
ical trials, which will be vital to achieve optimal onco-
logical, functional, and sexual outcomes, bearing in mind 
the high risk of cancer progression in this group of patients. 
THE SURGICAL APPROACH AS PART OF 
MULTIMODAL THERAPY 
With respect to the treatment of high- and very-high-risk 
PC in general, the failure of RRP or RT alone 
(monotherapy) is well recognized, and multimodal therapy 
may be needed. In well-selected patients, RP combined 
with adjuvant or salvage treatment when needed may re-
sult in better outcomes than RT alone, similar to the combi-
nation of RT plus hormone therapy [9]. Definitive therapy 
for high-risk PC, often requiring a multimodal approach, 
appears to provide the greatest long-term survival benefit. 
According to the recent EAU guidelines, patients must be 
informed about the possible need for a multimodal ap-
proach because neoadjuvant hormone therapy has not 
been shown to increase BPFS and OS and is not recom-
mended in these guidelines [6,53,54]. 
Although hormone therapy may decrease the size of the 
tumor and prostate overall, hormone therapy can induce 
a mild-to-moderate desmoplastic reaction around the pros-
tate, obscuring tissue planes around the periprostatic 
fascia. In a minority of patients, dissection of the prerectal 
planes is difficult, and the rectum can be adherent to the 
posterior prostate. In addition, RP in an extremely small 
prostate after hormone therapy can be slightly more 
challenging. This added challenge is mostly due to the des-
moplastic reaction as well as to difficulty in identifying the 
contours of the prostate and the normal tissue planes for 
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neurovascular preservation [25]. 
Adjuvant hormone therapy has a definite role in the 
management of high-risk patients after RP. Adjuvant hor-
mone therapy has its most relevant clinical utility after RP 
in node-positive patients. However, the effect of adjuvant 
ADT on OS remains unclear, and it appears to be influenced 
by the individual risk profile. The classic study of Messing 
et al. [37,55] demonstrated improvement in PSA- and can-
cer-free survival and OS for hormone therapy immediately 
following RP for node-positive PC. More recently, Boorjian 
et al. [56] analyzed data for 507 patients with node-positive 
PC following RP. In this trial, patients with immediate 
ADT had a statistically significantly decreased risk of bio-
chemical and local recurrence. There was no statistically 
significant difference, however, in the rate of systemic pro-
gression or CSS between the two groups. Therefore, the ad-
vantages of adjuvant hormone therapy after RP are 
debatable. 
Recently, Lee et al. [57] evaluated the competing risks 
of CSM after initial therapy with RP versus RT in men with 
clinically localized high-risk PC. Their study had several 
differences compared with previous reports: (1) relatively 
long follow-up periods; (2) RP performed by a single sur-
geon; and (3) the first data in an Asian population. They 
demonstrated that 5-year estimates of CSS rates for men 
treated with RP and RT were 96.5% (95% confidence inter-
val [CI], 94.2–98.9) and 88.3% (95% CI, 82.8–94.3), 
respectively. Cumulative incidence estimates for CSM us-
ing competing risks were statistically lower in men receiv-
ing RP versus RT (p=0.002). They summarized that initial 
treatment with RP versus RT was associated with a de-
creased risk of CSM in men with clinically localized 
high-risk PC.
Definitive results from a large randomized trial are war-
ranted to define the role of adjuvant hormone therapy in 
high-risk PC. Hormone therapy has also been investigated 
as an adjuvant therapy to RP in high-risk PC patients, even 
though few randomized trials are available. Postoperative 
adjuvant RT after RP for high-risk PC also remains 
controversial. The results of three randomized trials of 
postoperative adjuvant RT in high-risk patients, typically 
categorized by adverse pathology, such as pathologic stage 
T3-4N0 with PSM, extracapsular extension of disease, or 
seminal vesicle invasion, have been reported. All detected 
improvements in BPFS were in association with accept-
able rates of toxicity [58-60]. However, only one trial, a sec-
ondary analysis of the Southwest Oncology Group 8794 tri-
al, noted marked improvement in OS following post-
operative adjuvant RT [61]. 
CONCLUSIONS
Currently, surgery for high-risk PC is applied frequently. 
Nevertheless, this approach is still controversial. Because 
there is no standard definition of high-risk PC, outcome 
comparisons between series and treatment approaches are 
hampered. However, RP can provide durable local control, 
long-term CSS, and accurate pathologic staging and may 
guide further individualized treatment. RP with extended 
pelvic lymphadenectomy delivers very good cancer-related 
outcomes in high- and very-high-risk PC, often within a 
multimodal approach. Definitive results from a large 
randomized trial are warranted to define the role of ad-
juvant hormone therapy and RT in high-risk PC. 
Minimally invasive surgery is showing promising results, 
but further studies are needed to support its role compared 
to open RP and e-PLND as the gold standard. 
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